Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cryptococcal Meningitis
Conditions
Cryptococcal Meningitis
Trial Timeline
Aug 1, 2006 → —
NCT ID
NCT00847678About Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine
Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine is a phase 2 stage product being developed by Novartis for Cryptococcal Meningitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00847678. Target conditions include Cryptococcal Meningitis.
What happened to similar drugs?
0 of 2 similar drugs in Cryptococcal Meningitis were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00847678 | Phase 2 | Terminated |
Competing Products
18 competing products in Cryptococcal Meningitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mycograb + placebo | Novartis | Phase 2 | 27 |
| Single dose liposomal Amphotericin and Fluconazole + Fluconazole | Gilead Sciences | Phase 2/3 | 45 |
| Fluconazole | Pfizer | Pre-clinical | 26 |
| Fluconazole | Pfizer | Pre-clinical | 26 |
| Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 26 |
| Flucytosine + Fluconazole | Pfizer | Pre-clinical | 26 |
| Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 26 |
| Flucytosine + Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 26 |
| Fluconazole | Pfizer | Pre-clinical | 26 |
| Fluconazole | Pfizer | Pre-clinical | 26 |
| Fluconazole + Amphotericin B | Pfizer | Phase 3 | 40 |
| Flucytosine + Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 26 |
| Fluconazole | Pfizer | Pre-clinical | 26 |
| Lobradimil + Amphotericin B | Alkermes | Phase 1 | 26 |
| Flucytosine and fluconazole + Fluconazole | Bausch Health | Phase 2 | 21 |
| MAT2203 + Amphotericin B | Matinas Biopharma | Phase 1/2 | 22 |
| Encochleated Amphotericin B | Matinas Biopharma | Phase 1/2 | 14 |
| MAT2203 + Amphotericin B | Matinas Biopharma | Phase 3 | 26 |